uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
作者： S. Meng , D. Tripathy , S. Shete , R. Ashfaq , H. Saboorian
关键词: Regulation of gene expression 、 Trastuzumab 、 Immunology 、 Gene 、 Circulating tumor cell 、 Gene duplication 、 Breast cancer 、 Cancer research 、 Antibody 、 Biology 、 Urokinase receptor
摘要: Overexpression of urokinase plasminogen activator system or HER-2 (erbB-2) in breast cancer is associated with a poor prognosis. overexpression caused by gene amplification. The anti-HER-2 antibody trastuzumab significantly improves clinical outcome for HER2-positive cancer. Drugs that target the uPA are early trials. aims this study were to determine whether receptor (uPAR) amplification occurs and analysis individual tumor cells (TCs) blood tissue can add information conventional pathological could help diagnosis treatment. Analysis TCs indicates uPAR significant portion primary cancers also circulating (CTCs) from patients advanced disease. There was complete concordance between touch preps (TPs) examination status tumors. excellent tumors CTCs provided acquisition taken into account. Unexpectedly, occurred most frequently same TC patient, suggesting biological bias potential advantage coamplification. Expression predicted 100 92% patients, respectively.
harvard.edu
elsevier.com
utsystem.edu参考文章(34)
Marta Salido, Ignasi Tusquets, Josep M Corominas, Marta Suarez, Blanca Espinet, Cristina Corzo, Meritxell Bellet, Xavier Fabregat, Sergi Serrano, Francesc Solé, Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry Breast Cancer Research. ,vol. 7, pp. 1- 7 ,(2005) , 10.1186/BCR996
Nicolai Sidenius, Francesco Blasi, The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer and Metastasis Reviews. ,vol. 22, pp. 205- 222 ,(2003) , 10.1023/A:1023099415940
Ichiro Mori, Kennichi Kakudo, Yasushi Nakamura, Misa Nakamura, Bo Han, Urokinase-type plasminogen activator system and breast cancer (Review). Oncology Reports. ,vol. 14, pp. 105- 112 ,(2005) , 10.3892/OR.14.1.105
Arthur I Sagalowsky, David Euhus, Peter Beitsch, Larry Morrison, Chandra Rao, Nancy Lane, Jonathan Uhr, Songdong Meng, Edward Clifford, Hossein Saboorian, Thomas Tucker, B. Michael Ghadimi, Thomas Ried, Tanja Fehm, Kerstin Heselmeyer-Haddad, Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clinical Cancer Research. ,vol. 8, pp. 2073- 2084 ,(2002)
Anna Berkenblit, Ursula A. Matulonis, Joan F. Kroener, Bruce J. Dezube, Gil N. Lam, Luceli C. Cuasay, Nils Brünner, Terence R. Jones, Michael H. Silverman, Michael A. Gold, A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer : A phase I trial Gynecologic Oncology. ,vol. 99, pp. 50- 57 ,(2005) , 10.1016/J.YGYNO.2005.05.023
Rohit Bhargava, William L Gerald, Allan R Li, Qiulu Pan, Priti Lal, Marc Ladanyi, Beiyun Chen, EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR -activating mutations Modern Pathology. ,vol. 18, pp. 1027- 1033 ,(2005) , 10.1038/MODPATHOL.3800438
Christina H. Yeon, Mark D. Pegram, Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Investigational New Drugs. ,vol. 23, pp. 391- 409 ,(2005) , 10.1007/S10637-005-2899-8
J H de Witte, J A Foekens, N Brünner, J J T M Heuvel, ThH van Tienoven, M P Look, J G M Klijn, A Geurts-Moespot, N Grebenchtchikov, ThJ Benraad, C G J Sweep, Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours British Journal of Cancer. ,vol. 85, pp. 85- 92 ,(2001) , 10.1054/BJOC.2001.1867
Marilyn A. Owens, Bruce C. Horten, Moacyr M. Da Silva, HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clinical Breast Cancer. ,vol. 5, pp. 63- 69 ,(2004) , 10.3816/CBC.2004.N.011
C. Duggan, T. Maguire, E. McDermott, N. O'Higgins, J. J. Fennelly, M. J. Duffy, Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer International Journal of Cancer. ,vol. 61, pp. 597- 600 ,(1995) , 10.1002/IJC.2910610502